NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders.

[NeuroDerm @NeuroDerm]

We are wrapping up 2017 and are excited for everything to come from our #Parkinsons clinical trial research in 2018! #UniteForParkinsons

[NeuroDerm @NeuroDerm]

Thanks to @DavisPhinneyFND for including us in The Victory Summit Oklahoma City! #UniteForParkinsons

[NeuroDerm @NeuroDerm]

#DYK loss of sense of smell is an early sign of #Parkinsons? Learn more at @MichaelJFoxOrg https://t.co/uRy1YCFSl4

[NeuroDerm @NeuroDerm]

Such a great day yesterday with @ParkinsonDotOrg for #MovingDayMiami at Museum Park!

[NeuroDerm @NeuroDerm]

#DYK approximately 60,000 Americans are diagnosed with #Parkinsons disease each year? #UniteForParkinsons

[NeuroDerm @NeuroDerm]

We are proud to share the completion of our acquisition w/ @MTPharmaUS, & will continue developing treatments for people with #Parkinsons

[NeuroDerm @NeuroDerm]

$NDRM Announces Extraordinary General Meeting of Shareholders to Approve Acq. by Mitsubishi Tanabe Pharma Corp: https://t.co/sD7BF4HGRo

[NeuroDerm @NeuroDerm]

$NDRM Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash: https://t.co/H8H9kXgZKF

[NeuroDerm @NeuroDerm]

Results of @NeuroDerm ND0612H Phase II Trial Presented at the 3rd Congress of the European Academy of Neurology https://t.co/oRXkGQ9gsI

[NeuroDerm @NeuroDerm]

NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders - https://t.co/Bf5IxzQKzJ

[NeuroDerm @NeuroDerm]

European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial $NDRM - https://t.co/e8Lb8cqRsE

[NeuroDerm @NeuroDerm]

$NDRM Presents ND0612H Ph. II Trial Results at the 21st Intl. Congress of Parkinson’s Disease + Movement Disorders https://t.co/DS33gsEY6o

[NeuroDerm @NeuroDerm]

NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017 - https://t.co/ADbJG7cw2c

[NeuroDerm @NeuroDerm]

ND0612H Ph. 2 Results to be Presented at the 21st International Congress of Parkinson’s Disease + Movement Disorders https://t.co/CLGAv2QYyl

[NeuroDerm @NeuroDerm]

NeuroDerm Announces First Quarter 2017 Financial Results $NDRM - https://t.co/SJXUnPag4G

[NeuroDerm @NeuroDerm]

NeuroDerm is proud to participate in this year’s #PUW2017 and help to make a difference @unitywalk #uniteforparkinsons

[NeuroDerm @NeuroDerm]

Oded Lieberman, CEO, introducing ND0901, a pre-clinical continuous subcutaneous LD/CD delivery, at our Investor Day. https://t.co/ga2PYDnaGF

[NeuroDerm @NeuroDerm]

NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk - https://t.co/std6EwLlHC

[NeuroDerm @NeuroDerm]

NeuroDerm #UniteForParkinsons
A minute can make a huge difference in the lives of Parkinson’s patients and worldwide awareness!

[NeuroDerm @NeuroDerm]

NeuroDerm to Host Investor Day on April 21, 2017 - https://t.co/n5SgFBPT6O